Pharmicell announced on the 28th that, following resolutions at the general shareholders' meeting and the board of directors, it will transition from a sole representative system under Kim Hyun-soo to a dual representative system with Kim Hyun-soo and Yoon Yeon-soo as co-CEOs.
Going forward, CEO Kim Hyun-soo will focus on research and development, while newly appointed CEO Yoon Yeon-soo will be responsible for establishing and executing vision and strategies related to business operations.
CEO Yoon, who joined Pharmicell in January this year, graduated from Seoul National University Law School in 1986 and passed the 31st Judicial Examination. He also obtained a New York State Bar license. He worked in corporate advisory and international arbitration at law firms Sejong and Kwangjang. He served as a professor at KAIST Graduate School of Technology Management, lecturing on corporate law.
Pharmicell aims to promote efficient business operations by dividing its continuously expanding company tasks into research and development and business sectors through the appointment of co-CEOs.
A Pharmicell official explained, "As the company rapidly grows, CEO Kim's management burden has increased," adding, "CEO Kim has decided to focus on research and development of Pharmicell's core products, including stem cell therapeutics and nucleoside product lines, which are raw materials for gene therapy."
He continued, "We expect CEO Yoon to greatly contribute to the expansion of Pharmicell's business division," and added, "Following the transition to a dual representative system, the company's operation through separation and focus will create significant synergy effects."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
